Study conducted by ViiV Healthcare shows effectiveness of two drug HIV treatment

The pharmaceutical company recently unveiled late stage data that shows their experimental two-drug regimen of its dolutegravir and Janssen Science’s rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients. The dolutegravir/rilpivirine combination treatment achieved non-inferior viral suppression at 48 weeks compared with a three- or four-drug regimen in both

Continue Reading